Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study Assessing the Tolerance and Efficacy of Tamoxifen Alone Versus the Association Tamoxifen-RAD001 (Everolimus) in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

NCT01298713 is registered in ClinicalTrials.gov with ARCAGY/ GINECO GROUP as lead sponsor.

NCT NCT01298713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01298713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study Assessing the Tolerance and Efficacy of Tamoxifen Alone Versus the Association Tamoxifen-RAD001 (Everolimus) in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
Lead sponsor
ARCAGY/ GINECO GROUP
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2008
Completion date
September 12, 2018
Enrollment
111 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, mtor protein